Gilder Gagnon Howe & CO LLC Iovance Biotherapeutics, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.56 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding IOVA
# of Institutions
342Shares Held
247MCall Options Held
2.51MPut Options Held
3.5M-
Vanguard Group Inc Valley Forge, PA27.5MShares$98 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$86.9 Million24.02% of portfolio
-
Perceptive Advisors LLC New York, NY22.1MShares$78.7 Million5.46% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$75.6 Million0.0% of portfolio
-
State Street Corp Boston, MA12.2MShares$43.6 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $562M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...